Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by venture009on Jan 01, 2024 4:06pm
150 Views
Post# 35806246

RE:Happy new year, surprise is unfolding…

RE:Happy new year, surprise is unfolding…Canadafan, I lean more to them announcing they are going it alone, which I don't feel is beneficial to the shareholders. RS would be ineviable to raise cash and maintain their listing on the NASDQ. The reason I think this is, why commit to a conference in January if your status as a company has changed to be controlled by a BP? Also, if you're going it alone you no longer need a business developement executive hence the sudden departure of de G and no announcement. If you have a partner or sold there wouldn't need to be a sudden cutting of management until the partnership b/o was announced.  Coffey said 5 years ago he would only start b/o negiotations at $1.5 billion and I am certain he thinks it's worth more now, however, the sp is saying the opposite and a BP could buy a large % without committing the big $.  Plus this is Coffey's own pet science project and he has no concerns for the interests of the shareholder . He wants to see this come to market or die trying. Like you I believe we will know the fate very soon. As I have said in the past there is one thing you can depend on from ONC and that is this company always disappoints. 
<< Previous
Bullboard Posts
Next >>